Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 3Recruiting 2Completed 2Unknown 1No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 6392Neoplasms 5365Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1552Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 976Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

radium Ra 223 dichloride 1enzalutamide 1abiraterone 1Radium-223 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Clear all
NCT04862091 2022-03-04

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
69 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03896984 2021-12-29

PHENIX

Bayer

Completed
346 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡